Determinants of B-Cell Compartment Hyperactivation in European Adolescents Living With Perinatally Acquired HIV-1 After Over 10 Years of Suppressive Therapy
Copyright © 2022 Ruggiero, Pascucci, Cotugno, Domínguez-Rodríguez, Rinaldi, Tagarro, Rojo, Foster, Bamford, De Rossi, Nastouli, Klein, Morrocchi, Fatou, Smolen, Ozonoff, Di Pastena, Luzuriaga, Steen, Giaquinto, Goulder, Rossi, Levy, Pahwa, Palma and the EPIICAL Consortium..
Background: Despite a successful antiretroviral therapy (ART), adolescents living with perinatally acquired HIV (PHIV) experience signs of B-cell hyperactivation with expansion of 'namely' atypical B-cell phenotypes, including double negative (CD27-IgD-) and termed age associated (ABCs) B-cells (T-bet+CD11c+), which may result in reduced cell functionality, including loss of vaccine-induced immunological memory and higher risk of developing B-cells associated tumors. In this context, perinatally HIV infected children (PHIV) deserve particular attention, given their life-long exposure to chronic immune activation.
Methods: We studied 40 PHIV who started treatment by the 2nd year of life and maintained virological suppression for 13.5 years, with 5/40 patients experiencing transient elevation of the HIV-1 load in the plasma (Spike). We applied a multi-disciplinary approach including immunological B and T cell phenotype, plasma proteomics analysis, and serum level of anti-measles antibodies as functional correlates of vaccine-induced immunity.
Results: Phenotypic signs of B cell hyperactivation were elevated in subjects starting ART later (%DN T-bet+CD11c+ p=0.03; %AM T-bet+CD11c+ p=0.02) and were associated with detectable cell-associated HIV-1 RNA (%AM T-bet+CD11c+ p=0.0003) and transient elevation of the plasma viral load (spike). Furthermore, B-cell hyperactivation appeared to be present in individuals with higher frequency of exhausted T-cells, in particular: %CD4 TIGIT+ were associated with %DN (p=0.008), %DN T-bet+CD11c+ (p=0.0002) and %AM T-bet+CD11c+ (p=0.002) and %CD4 PD-1 were associated with %DN (p=0.048), %DN T-bet+CD11c+ (p=0.039) and %AM T-bet+CD11c+ (p=0.006). The proteomic analysis revealed that subjects with expansion of these atypical B-cells and exhausted T-cells had enrichment of proteins involved in immune inflammation and complement activation pathways. Furthermore, we observed that higher levels of ABCs were associated a reduced capacity to maintain vaccine-induced antibody immunity against measles (%B-cells CD19+CD10- T-bet+, p=0.035).
Conclusion: We identified that the levels of hyperactivated B cell subsets were strongly affected by time of ART start and associated with clinical, viral, cellular and plasma soluble markers. Furthermore, the expansion of ABCs also had a direct impact on the capacity to develop antibodies response following routine vaccination.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in immunology - 13(2022), Seite 860418 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ruggiero, Alessandra [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
B-cell hyperactivation |
|---|
| Anmerkungen: |
Date Completed 19.04.2022 Date Revised 30.11.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fimmu.2022.860418 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339618078 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339618078 | ||
| 003 | DE-627 | ||
| 005 | 20231226204523.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fimmu.2022.860418 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1132.xml |
| 035 | |a (DE-627)NLM339618078 | ||
| 035 | |a (NLM)35432380 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ruggiero, Alessandra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Determinants of B-Cell Compartment Hyperactivation in European Adolescents Living With Perinatally Acquired HIV-1 After Over 10 Years of Suppressive Therapy |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.04.2022 | ||
| 500 | |a Date Revised 30.11.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Ruggiero, Pascucci, Cotugno, Domínguez-Rodríguez, Rinaldi, Tagarro, Rojo, Foster, Bamford, De Rossi, Nastouli, Klein, Morrocchi, Fatou, Smolen, Ozonoff, Di Pastena, Luzuriaga, Steen, Giaquinto, Goulder, Rossi, Levy, Pahwa, Palma and the EPIICAL Consortium. | ||
| 520 | |a Background: Despite a successful antiretroviral therapy (ART), adolescents living with perinatally acquired HIV (PHIV) experience signs of B-cell hyperactivation with expansion of 'namely' atypical B-cell phenotypes, including double negative (CD27-IgD-) and termed age associated (ABCs) B-cells (T-bet+CD11c+), which may result in reduced cell functionality, including loss of vaccine-induced immunological memory and higher risk of developing B-cells associated tumors. In this context, perinatally HIV infected children (PHIV) deserve particular attention, given their life-long exposure to chronic immune activation | ||
| 520 | |a Methods: We studied 40 PHIV who started treatment by the 2nd year of life and maintained virological suppression for 13.5 years, with 5/40 patients experiencing transient elevation of the HIV-1 load in the plasma (Spike). We applied a multi-disciplinary approach including immunological B and T cell phenotype, plasma proteomics analysis, and serum level of anti-measles antibodies as functional correlates of vaccine-induced immunity | ||
| 520 | |a Results: Phenotypic signs of B cell hyperactivation were elevated in subjects starting ART later (%DN T-bet+CD11c+ p=0.03; %AM T-bet+CD11c+ p=0.02) and were associated with detectable cell-associated HIV-1 RNA (%AM T-bet+CD11c+ p=0.0003) and transient elevation of the plasma viral load (spike). Furthermore, B-cell hyperactivation appeared to be present in individuals with higher frequency of exhausted T-cells, in particular: %CD4 TIGIT+ were associated with %DN (p=0.008), %DN T-bet+CD11c+ (p=0.0002) and %AM T-bet+CD11c+ (p=0.002) and %CD4 PD-1 were associated with %DN (p=0.048), %DN T-bet+CD11c+ (p=0.039) and %AM T-bet+CD11c+ (p=0.006). The proteomic analysis revealed that subjects with expansion of these atypical B-cells and exhausted T-cells had enrichment of proteins involved in immune inflammation and complement activation pathways. Furthermore, we observed that higher levels of ABCs were associated a reduced capacity to maintain vaccine-induced antibody immunity against measles (%B-cells CD19+CD10- T-bet+, p=0.035) | ||
| 520 | |a Conclusion: We identified that the levels of hyperactivated B cell subsets were strongly affected by time of ART start and associated with clinical, viral, cellular and plasma soluble markers. Furthermore, the expansion of ABCs also had a direct impact on the capacity to develop antibodies response following routine vaccination | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a B-cell hyperactivation | |
| 650 | 4 | |a CD11c | |
| 650 | 4 | |a T-bet | |
| 650 | 4 | |a caHIV-1 RNA | |
| 650 | 4 | |a exhausted T-cells | |
| 650 | 4 | |a late ART | |
| 650 | 4 | |a perinatal HIV/AIDS | |
| 650 | 4 | |a proteomic profiling immune activation | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 700 | 1 | |a Pascucci, Giuseppe Rubens |e verfasserin |4 aut | |
| 700 | 1 | |a Cotugno, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Domínguez-Rodríguez, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Rinaldi, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Tagarro, Alfredo |e verfasserin |4 aut | |
| 700 | 1 | |a Rojo, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Foster, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Bamford, Alasdair |e verfasserin |4 aut | |
| 700 | 1 | |a De Rossi, Anita |e verfasserin |4 aut | |
| 700 | 1 | |a Nastouli, Eleni |e verfasserin |4 aut | |
| 700 | 1 | |a Klein, Nigel |e verfasserin |4 aut | |
| 700 | 1 | |a Morrocchi, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Fatou, Benoit |e verfasserin |4 aut | |
| 700 | 1 | |a Smolen, Kinga K |e verfasserin |4 aut | |
| 700 | 1 | |a Ozonoff, Al |e verfasserin |4 aut | |
| 700 | 1 | |a Di Pastena, Michela |e verfasserin |4 aut | |
| 700 | 1 | |a Luzuriaga, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Steen, Hanno |e verfasserin |4 aut | |
| 700 | 1 | |a Giaquinto, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Goulder, Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Rossi, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Levy, Ofer |e verfasserin |4 aut | |
| 700 | 1 | |a Pahwa, Savita |e verfasserin |4 aut | |
| 700 | 1 | |a Palma, Paolo |e verfasserin |4 aut | |
| 700 | 0 | |a EPIICAL Consortium |e verfasserin |4 aut | |
| 700 | 1 | |a Cotton, Mark |e investigator |4 oth | |
| 700 | 1 | |a Barnabas, Shaun |e investigator |4 oth | |
| 700 | 1 | |a Puthanakit, Thanyawee |e investigator |4 oth | |
| 700 | 1 | |a Kuhn, Louise |e investigator |4 oth | |
| 700 | 1 | |a Yates, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Violari, Avy |e investigator |4 oth | |
| 700 | 1 | |a Otwombe, Kennedy |e investigator |4 oth | |
| 700 | 1 | |a Vaz, Paula |e investigator |4 oth | |
| 700 | 1 | |a Lain, Maria Grazia |e investigator |4 oth | |
| 700 | 1 | |a Nampossa, Tacilta |e investigator |4 oth | |
| 700 | 1 | |a Naniche, Denise |e investigator |4 oth | |
| 700 | 1 | |a Fernandez-Luis, Sheila |e investigator |4 oth | |
| 700 | 1 | |a Lopez, Elisa |e investigator |4 oth | |
| 700 | 1 | |a Peay, Holly |e investigator |4 oth | |
| 700 | 1 | |a Spyer, Moira |e investigator |4 oth | |
| 700 | 1 | |a Calvez, Vincent |e investigator |4 oth | |
| 700 | 1 | |a Marcelin, Anne-Genevieve |e investigator |4 oth | |
| 700 | 1 | |a Munoz, Maria Angeles |e investigator |4 oth | |
| 700 | 1 | |a Dalzini, Annalisa |e investigator |4 oth | |
| 700 | 1 | |a Petrara, Raffaella |e investigator |4 oth | |
| 700 | 1 | |a Gartner, Kathleen |e investigator |4 oth | |
| 700 | 1 | |a Armas, Lesley De |e investigator |4 oth | |
| 700 | 1 | |a Rajendra, Pahwa |e investigator |4 oth | |
| 700 | 1 | |a Pallikkuth, Suresh |e investigator |4 oth | |
| 700 | 1 | |a Persaud, Deborah |e investigator |4 oth | |
| 700 | 1 | |a Chomont, Nicolas |e investigator |4 oth | |
| 700 | 1 | |a Lichterfeld, Mathias |e investigator |4 oth | |
| 700 | 1 | |a Faggion, Silvia |e investigator |4 oth | |
| 700 | 1 | |a Pena, Daniel Gomez |e investigator |4 oth | |
| 700 | 1 | |a Oletto, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Nardone, Alessandra |e investigator |4 oth | |
| 700 | 1 | |a Zangari, Paola |e investigator |4 oth | |
| 700 | 1 | |a Cesare, Silvia Di |e investigator |4 oth | |
| 700 | 1 | |a Medri, Chiara |e investigator |4 oth | |
| 700 | 1 | |a Kolesova, Olga |e investigator |4 oth | |
| 700 | 1 | |a Paganin, Carla |e investigator |4 oth | |
| 700 | 1 | |a James, William |e investigator |4 oth | |
| 700 | 1 | |a Lindfors-Rossi, Inger |e investigator |4 oth | |
| 700 | 1 | |a Hassan, Shrabon Samiur |e investigator |4 oth | |
| 700 | 1 | |a Mazzetto, Francesca |e investigator |4 oth | |
| 700 | 1 | |a Akisinku, Hellen |e investigator |4 oth | |
| 700 | 1 | |a Chingandu, Musakanya |e investigator |4 oth | |
| 700 | 1 | |a Rocchi, Francesca |e investigator |4 oth | |
| 700 | 1 | |a Pepponi, Ilaria |e investigator |4 oth | |
| 700 | 1 | |a De Boer, Rob J |e investigator |4 oth | |
| 700 | 1 | |a Schroter, Juliane |e investigator |4 oth | |
| 700 | 1 | |a Giannuzzi, Viviana |e investigator |4 oth | |
| 700 | 1 | |a Yates, Andrew |e investigator |4 oth | |
| 700 | 1 | |a Morris, Sinead |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in immunology |d 2010 |g 13(2022), Seite 860418 |w (DE-627)NLM215811453 |x 1664-3224 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g pages:860418 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fimmu.2022.860418 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |h 860418 | ||